keyword
MENU ▼
Read by QxMD icon Read
search

Glargine

keyword
https://www.readbyqxmd.com/read/29335890/effectiveness-of-sodium-glucose-cotransporter-2-inhibitor-as-an-add-on-drug-to-glp-1-receptor-agonists-for-glycemic-control-of-a-patient-with-prader-willi-syndrome-a-case-report
#1
Yukio Horikawa, Mayumi Enya, Makie Komagata, Ken-Ichi Hashimoto, Masayo Kagami, Maki Fukami, Jun Takeda
INTRODUCTION: Diabetes patients with Prader-Willi syndrome (PWS) are obese because of hyperphagia; weight control by dietary modification and medicine is required for glycemic control. There are several recent reports showing the effectiveness of GLP-1 receptor agonists (GLP-1RAs) for diabetes treatment in PWS. CASE REPORT: A 36-year-old Japanese male patient was diagnosed with PWS at 10 years of age. At age 16 years, he was diagnosed with diabetes and began to take several kinds of oral hypoglycemic agents...
January 15, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29327888/safety-of-degludec-versus-glargine-in-type-2-diabetes
#2
Steven P Marso, John B Buse
No abstract text is available yet for this article.
November 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29327887/safety-of-degludec-versus-glargine-in-type-2-diabetes
#3
Riccardo Perfetti
No abstract text is available yet for this article.
November 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29327886/safety-of-degludec-versus-glargine-in-type-2-diabetes
#4
John A Tayek, Paul N N Danese, Michael S Smith
No abstract text is available yet for this article.
November 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29327885/safety-of-degludec-versus-glargine-in-type-2-diabetes
#5
Amie A Ogunsakin, Nidhi Jain, Samuel Dagogo-Jack
No abstract text is available yet for this article.
November 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29322308/quality-of-life-of-patients-with-type-1-diabetes-mellitus-using-insulin-analog-glargine-compared-with-nph-insulin-a-systematic-review-and-policy-implications
#6
REVIEW
Paulo H R F Almeida, Thales B C Silva, Francisco de Assis Acurcio, Augusto A Guerra Júnior, Vania E Araújo, Leonardo M Diniz, Brian Godman, Alessandra M Almeida, Juliana Alvares
INTRODUCTION: Insulin analog glargine (GLA) has been available as one of the therapeutic options for patients with type 1 diabetes mellitus to enhance glycemic control. Studies have shown that a decrease in the frequency of hypoglycemic episodes improves the quality of life (QoL) of diabetic patients. However, there are appreciable acquisition cost differences between different insulins. Consequently, there is a need to assess their impact on QoL to provide future guidance to health authorities...
January 10, 2018: Patient
https://www.readbyqxmd.com/read/29316176/effect-of-prandial-treatment-timing-adjustment-based-on-continuous-glucose-monitoring-in-patients-with-type-2-diabetes-uncontrolled-on-once-daily-basal-insulin-a-randomized-phase-iv-study
#7
Jacob Ilany, Hamad Bhandari, Dan Nabriski, Yoel Toledano, Noa Konvalina, Ohad Cohen
OBJECTIVE: To evaluate the glycemic control achieved by prandial once daily insulin glulisine injection timing adjustment based on continuous glucose monitoring sensor in comparison to once daily insulin glulisine injection before breakfast in type 2 diabetes patients uncontrolled on once daily basal insulin glargine. RESEARCH DESIGN AND METHODS: This was a 24-week open-label, randomized-controlled, multicenter trial. At the end of 8 weeks of basal insulin optimization period, patients with HbA1c ≥ 7...
January 8, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29316143/basal-insulin-peglispro-increases-lipid-oxidation-metabolic-flexibility-thermogenesis-and-ketone-bodies-compared-to-insulin-glargine-in-subjects-with-type-1-diabetes-mellitus
#8
Niels K Porksen, Helle Linnebjerg, Eric Chen Quin Lam, Parag Garhyan, Alok Pachori, Richard E Pratley, Steven R Smith
AIMS: When treated with basal insulin peglispro (BIL), patients with type 1 diabetes mellitus (T1DM) exhibit weight loss and lower prandial insulin requirements versus insulin glargine (GL), while total insulin requirements remain similar. One possible explanation is enhanced lipid oxidation and improved ability to switch between glucose and lipid metabolism with BIL. This study compared the effects of BIL and GL on glucose and lipid metabolism in subjects with T1DM. MATERIALS AND METHODS: Fifteen subjects with T1DM were enrolled into this open-label, randomised, crossover study, and received once-daily stable, individualised, subcutaneous doses of BIL and GL for 4 weeks each...
January 8, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29314667/clinical-characteristics-of-type-2-diabetes-patients-with-discordance-between-hba1c-and-fasting-plasma-glucose-in-the-real-world-an-analysis-of-the-orbit-study
#9
Hua Shu, Juming Lu, Puhong Zhang, Dongshan Zhu, Xian Li, Jiachao Ji, Fang Zhao, Linong Ji
BACKGROUND: We aimed to determine the clinical characteristics of type 2 diabetes patients on basal insulin therapy with inadequate glucose control due to discordance between glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) in the real world. METHODS: This was a retrospective analysis of data from the ORBIT study in China. Clinical characteristics of patients with discordance between HbA1c and FPG at baseline and at the end of 6 months of follow-up were analyzed using multinomial logistic regression in 4 study groups devided by HbA1c and FPG...
January 3, 2018: Diabetes/metabolism Research and Reviews
https://www.readbyqxmd.com/read/29313285/treatment-dosing-patterns-and-clinical-outcomes-for-patients-with-type-2-diabetes-starting-or-switching-to-treatment-with-insulin-glargine-300-units-per-milliliter-in-a-real-world-setting-a-retrospective-observational-study
#10
Shaloo Gupta, Hongwei Wang, Neil Skolnik, Liyue Tong, Ryan M Liebert, Lulu K Lee, Peter Stella, Anna Cali, Ronald Preblick
INTRODUCTION: Usage patterns and effectiveness of a longer-acting formulation of insulin glargine at a strength of 300 units per milliliter (Gla-300) have not been studied in real-world clinical practice. This study evaluated differences in dosing and clinical outcomes before and after Gla-300 treatment initiation in patients with type 2 diabetes starting or switching to treatment with Gla-300 to assess whether the benefits observed in clinical trials translate into real-world settings...
January 8, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29300101/quality-of-life-and-treatment-satisfaction-in-actual-clinical-practice-of-patients-with-type-1-diabetes-mellitus-t1dm-and-hypoglycemia-treated-with-insulin-degludec
#11
Edurne Lecumberri, Maite Ortega, Marta Iturregui, José Antonio Quesada, Clotilde Vázquez, Domingo Orozco
OBJECTIVE: The frequency of hypoglycemia in patients with T1DM is high and results in a poorer quality of life and low treatment satisfaction. The aim of our study is to demonstrate the effect of changing the basal insulin (glargine or detemir) to insulin degludec. METHODS: We conducted an observational analytical study on a cohort of 110 patients with T1DM. The patients were administered 3 questionnaires to assess treatment satisfaction (DTSQ-s), fear of hypoglycemia (HFS-II) and quality of life (EQ-5D), before the change and at 6 months...
January 4, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29289540/a-randomized-controlled-study-comparing-a-dpp4-inhibitor-linagliptin-and-basal-insulin-glargine-in-patients-with-type-2-diabetes-in-long-term-care-and-skilled-nursing-facilities-linagliptin-ltc-trial
#12
Guillermo E Umpierrez, Saumeth Cardona, David Chachkhiani, Maya Fayfman, Sahebi Saiyed, Heqiong Wang, Priyathama Vellanki, J Sonya Haw, Darin E Olson, Francisco J Pasquel, Theodore M Johnson
OBJECTIVES: Safe and easily implemented treatment regimens are needed for the management of patients with type 2 diabetes mellitus (T2DM) in long-term care (LTC) and skilled nursing facilities. DESIGN: This 6-month open-label randomized controlled trial compared the efficacy and safety of a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in LTC residents with T2DM. SETTINGS: Three LTC institutions affiliated with a community safety-net hospital, US Department of Veterans Affairs and Emory Healthcare System in Atlanta, Georgia...
December 27, 2017: Journal of the American Medical Directors Association
https://www.readbyqxmd.com/read/29278460/relationship-between-treatment-persistence-and-a1c-trends-among-patients-with-type-2-diabetes-newly-initiated-on-basal-insulin
#13
Fang Liz Zhou, Lin Xie, Chunshen Pan, Yuexi Wang, Neel Vaidya, Fen Ye, Ronald Preblick, Luigi Meneghini
This study examines the relationship between glycated hemoglobin (A1C) levels and treatment persistence with, or time to discontinuation of, basal insulin in patients with type 2 diabetes (T2D) newly initiating insulin. Claims data were extracted from the Optum™ Clinformatics database from January 2010 to June 2015. Adult patients with T2D initiating insulin glargine 100 U/mL (Gla-100) or insulin detemir (DET) with ≥1 A1C measurement during 12-month baseline and 18-month follow-up periods were included...
December 26, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29277378/assessment-of-hypoglycaemia-during-basal-insulin-therapy-temporal-distribution-and-risk-of-events-using-a-predefined-or-an-expanded-definition-of-nocturnal-events
#14
M C Riddle, G B Bolli, A Avogaro, M G Álvarez, A Merino-Trigo, E Boëlle-Le Corfec, P D Home
AIM: To describe in type 2 diabetes the 24-hour distribution of hypoglycaemia and compare the frequency of nocturnal events based on a predefined nocturnal window or an expanded interval, using illustrative data for two insulin glargine formulations. METHODS: Temporal distribution of hypoglycaemic events was assessed descriptively and by profile using participant-level data from three randomized trials comparing insulin glargine 300 U/mL (Gla-300) and 100 U/mL (Gla-100)...
December 11, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/29276400/challenges-and-unmet-needs-in-basal-insulin-therapy-lessons-from-the-asian-experience
#15
REVIEW
Wing Bun Chan, Jung Fu Chen, Su-Yen Goh, Thi Thanh Huyen Vu, Iris Thiele Isip-Tan, Sony Wibisono Mudjanarko, Shailendra Bajpai, Maria Aileen Mabunay, Pongamorn Bunnag
Basal insulin therapy can improve glycemic control in people with type 2 diabetes. However, timely initiation, optimal titration, and proper adherence to prescribed basal insulin regimens are necessary to achieve optimal glycemic control. Even so, glycemic control may remain suboptimal in a significant proportion of patients. Unique circumstances in Asia (eg, limited resources, management of diabetes primarily in nonspecialist settings, and patient populations that are predominantly less educated) coupled with the limitations of current basal insulin options (eg, risk of hypoglycemia and dosing time inflexibility) amplify the challenge of optimal basal insulin therapy in Asia...
2017: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
https://www.readbyqxmd.com/read/29275373/randomized-trial-of-the-effects-of-insulin-and-metformin-on-myocardial-injury-and-stress-in-diabetes-mellitus-a-post-hoc-exploratory-analysis
#16
Pratyaksh K Srivastava, Aruna D Pradhan, Nancy R Cook, Paul M Ridker, Brendan M Everett
BACKGROUND: Subclinical myocardial injury, as measured by high-sensitivity cardiac troponin T (hsTnT), and myocardial stress, as measured by N-terminal pro-B-type natriuretic peptide (NT-proBNP), are related to glycemic control in patients with type 2 diabetes mellitus, and are strong predictors of adverse cardiovascular outcomes. We sought to determine whether antihyperglycemic therapy improves measures of myocardial injury and myocardial stress in patients with type 2 diabetes mellitus...
December 23, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29275047/reduced-lordosis-and-enhanced-aggression-in-paced-and-non-paced-mating-in-diabetic-female-rats
#17
Abigail K Hernández-Munive, Daniela Rebolledo-Solleiro, Elisa Ventura-Aquino, Alonso Fernández-Guasti
BACKGROUND: Clinical studies have shown altered sexual function in people with diabetes; basic science studies, using the streptozotocin (STZ)-induced animal model of type 1 diabetes mellitus (DM1), have consistently reported decreased sexual behavior in hyperglycemic female animals, but features of sexual motivation and aggressive behavior have not been explored in these animals. AIM: To study several parameters that denote sexual motivation in STZ-treated female rats and to compare behavioral features of sexual behavior and aggression in non-paced mating (NPM) and paced mating (PM) conditions...
December 20, 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/29241887/basal-insulin-regimens-for-adults-with-type-1-diabetes-mellitus-a-cost-utility-analysis
#18
Dalia Dawoud, Elisabetta Fenu, Bernard Higgins, David Wonderling, Stephanie A Amiel
OBJECTIVES: To assess the cost-effectiveness of basal insulin regimens for adults with type 1 diabetes mellitus in England. METHODS: A cost-utility analysis was conducted in accordance with the National Institute for Health and Care Excellence reference case. The UK National Health Service and personal and social services perspective was used and a 3.5% discount rate was applied for both costs and outcomes. Relative effectiveness estimates were based on a systematic review of published trials and a Bayesian network meta-analysis...
December 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29241884/the-use-of-decomposition-methods-in-real-world-treatment-benefits-evaluation-for-patients-with-type-2-diabetes-initiating-different-injectable-therapies-findings-from-the-initiator-study
#19
COMPARATIVE STUDY
Lee Brekke, Erin Buysman, Michael Grabner, Xuehua Ke, Lin Xie, Onur Baser, Wenhui Wei
BACKGROUND: Determining characteristics of patients likely to benefit from a particular treatment could help physicians set personalized targets. OBJECTIVES: To use decomposition methodology on real-world data to identify the relative contributions of treatment effects and patients' baseline characteristics. METHODS: Decomposition analyses were performed on data from the Initiation of New Injectable Treatment Introduced after Antidiabetic Therapy with Oral-only Regimens (INITIATOR) study, a real-world study of patients with type 2 diabetes started on insulin glargine (GLA) or liraglutide (LIRA)...
December 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29232162/efficacy-and-safety-of-biosimilar-sar342434-insulin-lispro-in-adults-with-type-2-diabetes-also-using-insulin-glargine-sorella-2-study
#20
Karl-Michael Derwahl, Timothy S Bailey, Karin Wernicke-Panten, Lin Ping, Suzanne Pierre
BACKGROUND: SAR342434 (SAR-Lis) is a biosimilar (follow-on) of insulin lispro (U100; Humalog®; Ly-Lis). This study aimed to show similar efficacy, safety, and immunogenicity of SAR-Lis versus Ly-Lis in adult patients with type 2 diabetes mellitus (T2DM) treated with multiple daily injections, while using insulin glargine (GLA-100; Lantus®) as basal insulin. METHODS: SORELLA 2 was a 6-month, randomized, open-label, Phase 3 study (NCT02294474). Insulin doses were adjusted to achieve fasting and 2-h postprandial glucose targets according to American Diabetes Association guidelines...
December 12, 2017: Diabetes Technology & Therapeutics
keyword
keyword
25751
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"